ライフサイエンスコーパス: therapeutic hypothermia

1 e striatum and to assess the outcome of deep therapeutic hypothermia.

2 versial data are available on the effects of therapeutic hypothermia.

3 The primary outcome was the initiation of therapeutic hypothermia.

4 ere compared with patients who received mild therapeutic hypothermia.

5 ognosticate in postarrest patients receiving therapeutic hypothermia.

6 t hospital arrival and decreases the time to therapeutic hypothermia.

7 temperature seen during this period of mild therapeutic hypothermia.

8 in cardiogenic shock might benefit from mild therapeutic hypothermia.

9 ion in cardiac arrest survivors who received therapeutic hypothermia.

10 s in comatose, postarrest patients receiving therapeutic hypothermia.

11 Post-cardiac-arrest therapeutic hypothermia.

12 mains an accurate predictor of outcome after therapeutic hypothermia.

13 dations for cooling, and ongoing research on therapeutic hypothermia.

14 t neurological impairment is not affected by therapeutic hypothermia.

15 nse is effective, thus impeding induction of therapeutic hypothermia.

16 e queried regarding use of postresuscitation therapeutic hypothermia.

17 non-United States respondents had never used therapeutic hypothermia.

18 as an adjunctive neuroprotective therapy to therapeutic hypothermia.

19 to neonatal mortality and morbidity despite therapeutic hypothermia.

20 tin or placebo, in conjunction with standard therapeutic hypothermia.

21 nitor degree of block in patients undergoing therapeutic hypothermia.

22 ficantly increased among patients undergoing therapeutic hypothermia.

23 agent administration in patients undergoing therapeutic hypothermia.

24 nts may be used to manage overt shivering in therapeutic hypothermia.

25 Exposure: Induction of therapeutic hypothermia.

26 euromuscular blockade in patients undergoing therapeutic hypothermia.

27 cardiopulmonary resuscitation and the use of therapeutic hypothermia.

28 r cardiac arrest, who were treated with mild therapeutic hypothermia.

29 matose cardiac arrest survivors treated with therapeutic hypothermia.

30 after out-of-hospital cardiac arrest receive therapeutic hypothermia.

31 ent to beyond 72 hours in cases treated with therapeutic hypothermia.

32 ed eighteen patients (77%) were treated with therapeutic hypothermia.

33 that infections are a common complication of therapeutic hypothermia.

34 -term outcomes in patients treated with mild therapeutic hypothermia.

35 ypothermia (33 degrees C for 16 hrs) or mild therapeutic hypothermia 1 xenon (70% for 1 hr).

36 survived the observation period in the mild therapeutic hypothermia 1 xenon group while one animal i

37 Mild therapeutic hypothermia 1 xenon preserved cardiac output

38 Clinically, only the mild therapeutic hypothermia 1 xenon-treated animals showed s

39 ital cardiac arrest (6.0%) were treated with therapeutic hypothermia; 1524 of these patients (mean [S

40 m "targeted temperature management" replace "therapeutic hypothermia." 2) The jury opines that descri

41 Likewise, therapeutic hypothermia (30 degrees C) inhibited Drp1-S6

42 ypothermia, to simulate temperatures used in therapeutic hypothermia (32 degrees C), were subjected t

43 The planned duration of therapeutic hypothermia (32 degrees C-34 degrees C) in b

44 Studies showing the effectiveness of therapeutic hypothermia (32-34 degrees C) in postcardiac

45 domized, controlled trial comparing moderate therapeutic hypothermia (33 degrees C during the first 2

46 pigs were randomized to receive either mild therapeutic hypothermia (33 degrees C for 16 hrs) or mil

47 iglets were randomized to the following: (i) therapeutic hypothermia (33.5 degrees C from 2 to 26 h a

48 ients aged more than 75 frequently underwent therapeutic hypothermia (97.7%), urgent coronary angiogr

49 s, heart transplant, external defibrillation/therapeutic hypothermia, advances in surgical myectomy,

50 The protective mechanisms of therapeutic hypothermia affect the ischaemic cascade acr

51 Therapeutic hypothermia after cardiac arrest improves su

52 igorous exchange transfusion may enable mild therapeutic hypothermia after cardiac arrest in patients

53 Therapeutic hypothermia after cardiac arrest is feasible

54 sought to evaluate current physician use of therapeutic hypothermia after cardiac arrest, to ascerta

55 activation occurs during rewarming from mild therapeutic hypothermia after cardiac arrest.

56 considered a contraindication to the use of therapeutic hypothermia after cardiac arrest.

57 Seventy-five patients with CA treated with therapeutic hypothermia after cardiac resuscitation were

58 ight patients with cardiac arrest treated by therapeutic hypothermia after cardiac resuscitation were

59 In patients treated with therapeutic hypothermia after out-of-hospital cardiac ar

60 were for planning an interventional trial of therapeutic hypothermia after pediatric cardiac arrest.

61 lled trial evaluating the effect of (48 hrs) therapeutic hypothermia after severe traumatic brain inj

62 ital discharge in patients treated with mild therapeutic hypothermia after sudden cardiac arrest.

63 tive effects of combining inhaled xenon with therapeutic hypothermia after transient cerebral hypoxia

64 otective effects of combining melatonin with therapeutic hypothermia after transient hypoxia-ischaemi

65 sure, elevated intra-abdominal pressure, and therapeutic hypothermia after ventricular fibrillation-a

66 f the metabolic phase of cardiac arrest with therapeutic hypothermia, agents to treat or prevent repe

67 Despite treatment with therapeutic hypothermia, almost 50% of infants with neon

68 pothermia significantly better than did mild therapeutic hypothermia alone (4.6 6 0.6 L/min vs. 3.2 6

69 This study tested whether therapeutic hypothermia altered levels of inflammatory m

70 mmatory molecules, and it is unknown whether therapeutic hypothermia alters this inflammatory respons

71 Eighty-eight percent of patients underwent therapeutic hypothermia and 471 (18%) exhibited myoclonu

72 est on a large cohort of patients undergoing therapeutic hypothermia and at investigating its added v

73 scitated but comatose patients that includes therapeutic hypothermia and early catheterization/interv

74 Therapeutic hypothermia and extracorporeal membrane oxyg

75 efore, we tested the hypothesis whether mild therapeutic hypothermia and hyperoxia would attenuate po

76 pecific miRNAs were found to be sensitive to therapeutic hypothermia and may therefore be important t

77 sible association between bradycardia during therapeutic hypothermia and neurologic outcome in comato

78 spontaneous circulation who did not receive therapeutic hypothermia and never exceeded 37.5 degrees

79 acute inflammatory events are attenuated by therapeutic hypothermia and other anti-inflammatory stra

80 aggressive postresuscitation care, including therapeutic hypothermia and percutaneous coronary interv

81 Therapeutic hypothermia and pharmacological sedation may

82 tion with current clinical practices such as therapeutic hypothermia and pharmacologically induced co

83 Except for therapeutic hypothermia and revascularization, no novel

84 1ra did not significantly change during mild therapeutic hypothermia and rewarming, although low valu

85 time in cardiac arrest patients during mild therapeutic hypothermia and rewarming.

86 jective: To evaluate the association between therapeutic hypothermia and survival after in-hospital c

87 ns, strongly suggests an association between therapeutic hypothermia and the risk of pneumonia and se

88 However, only the combination of mild therapeutic hypothermia and xenon resulted in reduced as

89 Ninety-seven percent received therapeutic hypothermia, and overall survival was 46%.

90 This is the first case of therapeutic hypothermia applied to postarrest care of a

91 nvestigate whether the beneficial effects of therapeutic hypothermia are due to preserved autophagy a

92 Additional treatments for therapeutic hypothermia are required to maximize neuropr

93 vival and neurological outcomes benefit from therapeutic hypothermia are robust when compared over a

94 ntal outcomes when given in conjunction with therapeutic hypothermia are unknown.

95 tation care of cardiac arrest patients using therapeutic hypothermia as part of nontrial treatment.

96 available clinical evidence does not support therapeutic hypothermia as standard therapy for acute my

97 ren who survived in-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic no

98 who survived out-of-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic no

99 he hospital in both groups received systemic therapeutic hypothermia at 32 degrees C to 34 degrees C

100 ac arrest with nonshockable rhythm, moderate therapeutic hypothermia at 33 degrees C for 24 hours led

101 HI brain injury and guiding the titration of therapeutic hypothermia at the bedside.

102 Formal guidelines recommend that therapeutic hypothermia be considered after in-hospital

103 e associated with an increased likelihood of therapeutic hypothermia being initiated.

104 Therapeutic hypothermia blunts the expression of these m

105 Bradycardia is frequent during therapeutic hypothermia, but its impact on outcome remai

106 urvivors of cardiac arrest subjected to mild therapeutic hypothermia, but the underlying mechanisms a

107 ental and clinical data that examine whether therapeutic hypothermia can improve functional outcomes

108 Therapeutic hypothermia can improve survival after cardi

109 sing over the years, clinical application of therapeutic hypothermia cannot be recommended for routin

110 Conclusive efficacy trials assessing therapeutic hypothermia combined with reperfusion therap

111 ents with in-hospital cardiac arrest, use of therapeutic hypothermia compared with usual care was ass

112 To buy time, the induction of therapeutic hypothermia (core temperature 32 degrees C-3

113 and treatment by cardiac arrest centers for therapeutic hypothermia, coronary artery evaluation and

114 These findings suggest that mild therapeutic hypothermia could be a therapeutic option in

115 We hypothesize that systemic therapeutic hypothermia could decrease morbidity and mor

116 Therapeutic hypothermia decreases brain tissue injury in

117 rmia are arrhythmogenic, patients undergoing therapeutic hypothermia do not have an increase in arrhy

118 Therapeutic hypothermia during cardiac arrest and after

119 cal reports have suggested that induction of therapeutic hypothermia during cardiopulmonary resuscita

120 tal of 1198 patients were assigned to either therapeutic hypothermia during CPR (618 patients) or sta

121 One technique for induction of mild therapeutic hypothermia during CPR is a rapid infusion o

122 Overall 10.2% of patients allocated to therapeutic hypothermia during CPR were alive at hospita

123 In this randomized trial, mild therapeutic hypothermia failed to show a substantial ben

124 of outcome-modifying interventions, such as therapeutic hypothermia following cardiac arrest.

125 ular-blocking agents for patients undergoing therapeutic hypothermia following cardiac arrest.

126 rent studies have demonstrated that applying therapeutic hypothermia for 12 to 24 hours after resusci

127 Treatment with mild therapeutic hypothermia for 24 hours followed by passive

128 rwent randomization in a 1:1 fashion to mild therapeutic hypothermia for 24 hours or control.

129 ts from previous trials, we assessed whether therapeutic hypothermia for 48-72 h with slow rewarming

130 ular fibrillation who were treated with mild therapeutic hypothermia for 72 hrs.

131 Treatment with mild therapeutic hypothermia for 72 hrs.

132 We aimed to determine the use of therapeutic hypothermia for adult in-hospital cardiac ar

133 Although therapeutic hypothermia for cardiac arrest survivors has

134 ntal trials suggest improved outcome by mild therapeutic hypothermia for cardiogenic shock after acut

135 fficacy of methylxanthines in the setting of therapeutic hypothermia for HIE are limited.

136 domized clinical trial to assess efficacy of therapeutic hypothermia for in-hospital cardiac arrest.

137 With the current practice of therapeutic hypothermia for neonatal encephalopathy, dis

138 ing term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy.

139 Therapeutic hypothermia for post-MI cardiogenic shock ha

140 nt of novel therapeutic approaches to induce therapeutic hypothermia for treating drug-resistant feve

141 urs was significantly less in the Xenon+mild therapeutic hypothermia group (p=0.04).

142 er 90 days, 171 patients (63.6%) in the mild therapeutic hypothermia group and 129 (67.9%) in the tar

143 significantly higher in patients in the mild therapeutic hypothermia group with a slower decline ( P

144 e in outcomes 12 months after injury; in the therapeutic hypothermia group, four (17%) had a bad outc

145 rapeutic hypothermia group, n=17; Xenon+mild therapeutic hypothermia group, n=16).

146 Thirty-three patients were evaluable (mild therapeutic hypothermia group, n=17; Xenon+mild therapeu

147 ith target temperature of 33 degrees C (mild therapeutic hypothermia group, n=18) alone or in combina

148 et concentration of at least 40% (Xenon+mild therapeutic hypothermia group, n=18) for 24 hours.

149 utic hypothermia group=5.30 mg vs Xenon+mild therapeutic hypothermia group=2.95 mg, p=0.06).

150 ia was lower in xenon-treated patients (mild therapeutic hypothermia group=5.30 mg vs Xenon+mild ther

151 Therapeutic hypothermia has been shown in randomized cli

152 Therapeutic hypothermia has been shown to decrease neuro

153 Therapeutic hypothermia has been used to attenuate the e

154 Therapeutic hypothermia has demonstrated considerable be

155 Because positive hemodynamic effects of mild therapeutic hypothermia have been suggested, we aimed at

156 Therapeutic hypothermia (HT) is standard care for modera

157 Therapeutic hypothermia (HT) is standard care for term i

158 Therapeutic hypothermia (HT) to 33.0-34.0 degrees C for

159 Therapeutic hypothermia (HT), comprising the standard of

160 assigned brain-dead kidney donors to undergo therapeutic hypothermia (hypothermia group), ex situ kid

161 sedative requirements early in the course of therapeutic hypothermia improve the identification of pa

162 Whether therapeutic hypothermia improves important outcomes afte

163 Post-cardiac-arrest therapeutic hypothermia improves outcomes in comatose ca

164 Hemodynamic effects of mild therapeutic hypothermia in 20 consecutive patients admit

165 t study supporting a role of cooling caps in therapeutic hypothermia in adults.

166 Early therapeutic hypothermia in children with severe traumati

167 We excluded trials investigating therapeutic hypothermia in indications already supported

168 entation of "poor prognosis" occurred during therapeutic hypothermia in more than half of patients in

169 upport, hypoxic-ischemic encephalopathy, and therapeutic hypothermia in nonvigorous near-term and ful

170 ety of inhaled xenon treatment combined with therapeutic hypothermia in out-of-hospital cardiac arres

171 man data provides a rationale for the use of therapeutic hypothermia in patients with acute liver fai

172 investigate the hemodynamic effects of mild therapeutic hypothermia in patients with cardiogenic sho

173 However, the effectiveness of moderate therapeutic hypothermia in patients with nonshockable rh

174 option for early and effective induction of therapeutic hypothermia in settings of cardiopulmonary r

175 e neuroprotective effect of (prolonged) mild therapeutic hypothermia in the delayed hypoperfusion pha

176 Therapeutic hypothermia in the ICU requires mechanical v

177 apoE4 allele, with GCS score, sex, race, and therapeutic hypothermias included as covariates.

178 The use of therapeutic hypothermia increased from 0.7% in 2003 to 3

179 omized controlled trials, in that the use of therapeutic hypothermia increased survival with an odds

180 However, therapeutic hypothermia increases sepsis risk and uninte

181 Mild therapeutic hypothermia induced a significant decrease i

182 Therapeutic hypothermia induced a significant increase i

183 y investigated whether a shorter duration of therapeutic hypothermia induced quickly and early after

184 Therapeutic hypothermia initiated 0, 1, 4, and 8 hrs aft

185 Therapeutic hypothermia initiated with cardiopulmonary r

186 Despite the introduction of mild therapeutic hypothermia into postcardiac arrest care, ce

187 Therapeutic hypothermia is a highly promising treatment,

188 Early introduction of mild therapeutic hypothermia is an established treatment goal

189 h-quality randomized evidence indicates that therapeutic hypothermia is associated with higher mortal

190 Therapeutic hypothermia is associated with significantly

191 Therapeutic hypothermia is being clinically used to redu

192 ough there still might be a possibility that therapeutic hypothermia is beneficial in a specific sett

193 Therapeutic hypothermia is commonly used to improve neur

194 Moderate therapeutic hypothermia is currently recommended to impr

195 sis that the efficacy of post-cardiac-arrest therapeutic hypothermia is dependent on the onset and du

196 Therapeutic hypothermia is likely a beneficial treatment

197 Although therapeutic hypothermia is now established to improve re

198 Therapeutic hypothermia is recommended by international

199 Therapeutic hypothermia is recommended for comatose adul

200 Although therapeutic hypothermia is relatively easy to implement,

201 Importance: Therapeutic hypothermia is used for patients following b

202 Therapeutic hypothermia is widely employed for neuroprot

203 gnesium, phosphodiesterase 3 inhibitors, and therapeutic hypothermia, is emerging.

204 cardiac index remained unchanged under mild therapeutic hypothermia likely due to an increase in eje

205 The time to therapeutic hypothermia (<34 degrees C) was 3.2 hrs in t

206 Sedation with volatile anesthetics during therapeutic hypothermia may be a feasible short-acting o

207 These data suggest that therapeutic hypothermia may decrease arrhythmogenesis du

208 Mild therapeutic hypothermia may improve survival and neurolo

209 Therapeutic hypothermia may increase survival with good

210 Mild therapeutic hypothermia (MTH) has been integrated into i

211 s with ischemic heart disease, the effect of therapeutic hypothermia on arrhythmia susceptibility dur

212 The effects of therapeutic hypothermia on drug disposition include both

213 ctive cohort study, we examine the impact of therapeutic hypothermia on ER in survivors of cardiac ar

214 dies have demonstrated beneficial effects of therapeutic hypothermia on myocardial function, yet exac

215 To ascertain more precisely the effect of therapeutic hypothermia on neonatal cerebral injury, we

216 Our objective was to determine the effect of therapeutic hypothermia on oxidative damage after severe

217 of this study was to evaluate the impact of therapeutic hypothermia on phenytoin levels and pharmaco

218 This review examines the effects of therapeutic hypothermia on the disposition, metabolism,

219 Despite the association of ER with ID-VF, therapeutic hypothermia only increases ER amplitude in C

220 Increasingly, the use of therapeutic hypothermia or ketogenic diet is described a

221 rculation (OR, 7.628; 95% CI, 2.084-27.922), therapeutic hypothermia (OR, 4.320; 95% CI, 1.624-11.488

222 l cardiopulmonary resuscitation with/without therapeutic hypothermia, or sham groups.

223 For improved adoption of therapeutic hypothermia, our data suggest that developme

224 who had cardiac arrest and were treated with therapeutic hypothermia over a 7-year period were consid

225 ed accurate predictors of poor outcome after therapeutic hypothermia (p < 0.0001 for all).

226 e initial rhythms from the Penn Alliance for Therapeutic Hypothermia (PATH) registry between 2000 and

227 t rate was significantly lower in Xenon+mild therapeutic hypothermia patients during hypothermia (p=0

228 We measured the proportion of therapeutic hypothermia patients who achieved target tem

229 2-34 degrees C) was not achieved in 44.3% of therapeutic hypothermia patients within 24 hours and 17.

230 Patients admitted in the therapeutic hypothermia period had a mean esophageal tem

231 rvival to hospital discharge improved in the therapeutic hypothermia period in patients with an initi

232 ventricular fibrillation patients during the therapeutic hypothermia period trended toward improved s

233 The therapeutic hypothermia period was associated with a sig

234 During the therapeutic hypothermia period, 204 patients were brough

235 to 26 h after resuscitation, n = 8) and (ii) therapeutic hypothermia plus intravenous melatonin (5 mg

236 than 20 mm Hg after traumatic brain injury, therapeutic hypothermia plus standard care to reduce int

237 An active cooling therapeutic hypothermia protocol, using ice packs, cooli

238 crease or did not have documented use of the therapeutic hypothermia protocol.

239 the process of developing and implementing a therapeutic hypothermia protocol.

240 gic outcome at discharge associated with the therapeutic hypothermia protocol.

241 We conclude that in cardiogenic shock mild therapeutic hypothermia provides circulatory support and

242 c-ischemic encephalopathy who have undergone therapeutic hypothermia, quantitative magnetic resonance

243 Patients allocated to therapeutic hypothermia received a mean (SD) of 1193 (64

244 Although therapeutic hypothermia reduces death or disability afte

245 Accordingly, patients with mild therapeutic hypothermia required lower cumulative doses

246 In this study, post-cardiac-arrest therapeutic hypothermia resulted in comparable improveme

247 t exposure to xenon during induction of mild therapeutic hypothermia results in significant improveme

248 cardiac output during the induction of mild therapeutic hypothermia significantly better than did mi

249 Therapeutic hypothermia significantly reduces phenytoin

250 s), electroencephalography reactivity during therapeutic hypothermia, somatosensory-evoked potentials

251 both free and total levels demonstrated that therapeutic hypothermia specifically decreased the time-

252 spontaneous circulation with an endovascular therapeutic hypothermia system placed in the right atriu

253 an 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0 degree

254 an 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0 degree

255 Therapeutic hypothermia (TH) at 33.5 degrees C for 72 h

256 analysis of neonates with HIE who underwent therapeutic hypothermia (TH) at US children's hospitals

257 Therapeutic hypothermia (TH) attenuates reperfusion inju

258 Therapeutic hypothermia (TH) improves survival and confe

259 Treatment with therapeutic hypothermia (TH) improves the long-term neur

260 percutaneous coronary intervention (PCI) and therapeutic hypothermia (TH) on long-term prognosis.

261 After the beginning of mild therapeutic hypothermia, the patient experienced maligna

262 body weight >120 kg, and patients requiring therapeutic hypothermia to <28 C).

263 In all patients, we induced therapeutic hypothermia to 33 degrees C during the first

264 The intervention group had therapeutic hypothermia to a temperature of 32-33 degree

265 In therapeutic hypothermia-treated patients after out-of-ho

266 Twenty-one therapeutic hypothermia-treated patients after out-of-ho

267 ere randomly assigned to receive either mild therapeutic hypothermia treatment with target temperatur

268 vention without classic indications for mild therapeutic hypothermia underwent randomization in a 1:1

269 e sedation with the AnaConDa during 24 hours therapeutic hypothermia, until rewarming.

270 The rate of therapeutic hypothermia use after in-hospital cardiac ar

271 Factors associated with therapeutic hypothermia use included patient age, time a

272 patients with persisting coma after CPR and therapeutic hypothermia, use of motor score or NSE, as r

273 f-hospital cardiac arrest, induction of mild therapeutic hypothermia using a rapid infusion of large-

274 int of cardiac power index at 24 hours (mild therapeutic hypothermia versus control: 0.41 [interquart

275 Therapeutic hypothermia was also associated with lower r

276 Therapeutic hypothermia was associated with a reduction

277 Therapeutic hypothermia was associated with an increase

278 Bradycardia during therapeutic hypothermia was associated with good neurolo

279 After adjustment, therapeutic hypothermia was associated with lower in-hos

280 rformed, spontaneous perfusion restored, and therapeutic hypothermia was attempted for neural protect

281 CONCLUSIONS/SIGNIFICANCE: Therapeutic hypothermia was implemented appropriately wi

282 Among brain-dead organ donors, therapeutic hypothermia was inferior to machine perfusio

283 d 65% +/- 16%* of normal, respectively, when therapeutic hypothermia was initiated 0, 1, 4, or 8 hrs

284 Of 67,498 patients, therapeutic hypothermia was initiated in 1,367 patients

285 These outcomes were not different when therapeutic hypothermia was maintained for 24 vs. 48 hrs

286 e, surviving neuron counts were greater when therapeutic hypothermia was maintained for 48 hrs compar

287 utic window and greater neuroprotection when therapeutic hypothermia was maintained for 48 vs. 24 hrs

288 OR, 1.9 [1.4-2.6]), whereas no difference in therapeutic hypothermia was noted.

289 red the content of hemoglobin S to 5.6%, and therapeutic hypothermia was successfully maintained for

290 After in-hospital cardiac arrest, therapeutic hypothermia was used rarely.

291 ected of suffering asphyxial encephalopathy--therapeutic hypothermia- was implemented in the UK.

292 rrest rigorous exchange transfusion and mild therapeutic hypothermia were applied.

293 were kept normothermic, those who underwent therapeutic hypothermia were associated with 18% reducti

294 maging.Methods: Neonates with HIE undergoing therapeutic hypothermia were enrolled.

295 Patients undergoing therapeutic hypothermia were excluded.

296 tal of 55 consecutive patients who underwent therapeutic hypothermia were reviewed between September

297 thermia (<37.5 degrees C) compared with mild therapeutic hypothermia were studied.

298 cal and clinical studies have suggested that therapeutic hypothermia, while decreasing neurologic inj

299 postanoxic encephalopathy treated with mild therapeutic hypothermia within 24 hours after cardiac ar

300 n a specific setting, routine application of therapeutic hypothermia would better be avoided outside